Antheia’s 2022 in Review: A Year of Value

This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Drug Discovery and Development 2023 Predictions

Drug Discovery and Development highlighted key drug discovery and development predictions for 2023. Antheia was highlighted for its take on the synbio industry’s renewed focus on “how, as a global community…
Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production

In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency and variability within agricultural supply chains remains the number one challenge in the pharmaceutical-grade production…
Leveraging Fermentation to Produce Complex APIs

In this Contract Pharma Q&A, we sat down with Kristin Brooks to discuss how our company uses fermentation to produce complex APIs for essential medicines. Fermentation and synthetic biology have evolved dramatically…
Demystifying Synthetic Biology Part V: The Product is Key in Downstream Processing

Upstream bioprocessing – better known in biomanufacturing as fermentation – is directly followed by downstream bioprocessing (DSP). Just as fermentation is all about maximizing the production of a target compound, DSP focuses
Introducing Guerin Kob, Antheia’s VP of Supply Chain

With a pilot plant on the horizon and a pipeline filled with promise, Antheia is poised to soon establish a fermentation-based supply chain to produce the KSMs and APIs for essential medicines.
Demystifying Synthetic Biology IV: Fermentation Bioprocess Development

Fermentation is one of humanity’s oldest and most pivotal technological developments. Through fermentation, societies began adapting their diets nearly ten millennia ago, to include new and innovative foods such as alcohol and leavened bread…
Antheia Announces New Financing and Plans to Construct Pilot Plant Facility for Biomanufacturing
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility.
Demystifying Synthetic Biology III: The 21st Century Technologies Advancing Synthetic Biology

Synthetic biology is often touted as a software-driven and automation-empowered approach to biological research. Buzzwords like artificial intelligence and robotics are commonly used alongside the phrase synthetic biology, leading…
Introducing CPO Heidi Pucel

Growth and change can be challenging within dynamic, evolving startups, but it’s easier to navigate when you are tuned in to how people experience the world. Heidi Pucel, Antheia’s new Chief People Officer, knows a thing or two about this…